<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15078">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910583</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1142-CA</org_study_id>
    <nct_id>NCT02910583</nct_id>
  </id_info>
  <brief_title>Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma</brief_title>
  <official_title>Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research and Development LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the clinical minimum residual disease (MRD) response with the
      combination of ibrutinib plus venetoclax in subjects with treatment-naive chronic
      lymphocytic leukemia (CLL)/small lymphocytic lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRD-negative clinical response rate</measure>
    <time_frame>approximately 40 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>approximately 52 months</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Leukemia, Chronic Lymphocytic</condition>
  <condition>Lymphoma, Small Lymphocytic</condition>
  <arm_group>
    <arm_group_label>Pre-Randomization open-label ibrutinib + venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 420mg capsules of single-agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibrutinib (blinded)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects that are MRD-negative will be randomized to receive ibrutinib 420 mg capsules orally once daily on a continuous schedule until clinical disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo to match ibrutinib</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects that are MRD-negative will be randomized to receive matching ibrutinib placebo capsules orally once daily on a continuous schedule until MRD-positive relapse, clinical disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomization open-label ibrutinib + venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects that are MRD-positive will be randomized to receive ibrutinib 420 mg capsules and venetoclax 400mg tablets orally once daily on a continuous schedule until clinical disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects that are MRD-positive will be randomized to receive ibrutinib 420 mg capsules orally once daily on a continuous scheduled until clinical disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibrutinib</intervention_name>
    <description>ibrutinib 420mg capsules administered orally once daily</description>
    <arm_group_label>Pre-Randomization open-label ibrutinib + venetoclax</arm_group_label>
    <arm_group_label>Ibrutinib (blinded)</arm_group_label>
    <arm_group_label>Randomization open-label ibrutinib + venetoclax</arm_group_label>
    <arm_group_label>ibrutinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to match ibrutinib</intervention_name>
    <description>placebo capsules to match ibrutinib administered orally once daily</description>
    <arm_group_label>placebo to match ibrutinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venetoclax</intervention_name>
    <description>venetoclax tablets orally will be administered at 400mg once daily</description>
    <arm_group_label>Pre-Randomization open-label ibrutinib + venetoclax</arm_group_label>
    <arm_group_label>Randomization open-label ibrutinib + venetoclax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria (Hallek 2008), with active
             disease meeting at least 1 IWCLL criteria for requiring treatment.

          -  Measurable nodal disease by computed tomography (CT)

          -  Adequate hepatic, and renal function

          -  Adequate hematologic function

               -  absolute neutrophil count &gt;750/µL

               -  platelet count &gt;30,000 /μL

               -  hemoglobin &gt;8.0 g/dL

        Exclusion Criteria:

          -  Any prior therapy used for treatment of CLL/SLL

          -  Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk
             for TLS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristin Russell</last_name>
    <phone>408-215-3508</phone>
    <email>krussell@pcyc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yun Shaw</last_name>
    <phone>408-215-3383</phone>
    <email>yshaw@pcyc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 047</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 7, 2016</lastchanged_date>
  <firstreceived_date>September 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
